Lung Non-Small Cell Carcinoma

High levels of Aurora-A expression (retrospectively assessed by IHC in 102 NSCLC patients) predicted poorer overall survival and progression free survival in a population treated with surgery and cisp… (full text at CIViC)

PMID 25082261 · Xu et al., 2014 · Open in CIViC

A patient with lung adenocarcinoma harboring a somatic homozygous BARD1 G320* stop-gain alteration and an RBBP8 exon 3–4 duplication was classified as homologous recombination deficient by HRDetect an… (full text at CIViC)

PMID 36964191 · Tsang et al., 2023 · Open in CIViC

The BIM (BCL2L11) deletion polymorphism was identified in an EGFR Mutant NSCLC cell line with resistance to EGFR-TKI (HCC2779). Introduction of this polymorphism in a previously EGFR-inhibitor sensiti… (full text at CIViC)

PMID 22426421 · Ng et al., 2012 · Open in CIViC

Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective anal… (full text at CIViC)

PMID 24961465 · Wu et al., 2014 · Open in CIViC

Non-V600 BRAF mutations occur frequently in NSCLC. While BRAF D594E results in impaired kinase activity, it can induce MEK/ERK activation in the presence of RAF1 (CRAF). BEAS-2B lung epithelial cell l… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

Non-V600 BRAF mutations occur frequently in NSCLC. While BRAF D594N results in impaired kinase activity, it can induce MEK/ERK activation when expressed in HEK293T cells in the presence of RAF1 (CRAF)… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell-growth and impact on signalling was measured: ERK signalling by wester… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

In the BRAF G466V-mutant NCI-H1666 model, NST-628 suppressed MAPK signaling without inducing BRAF–CRAF heterodimer formation. NCI-H1666 was also included in a panel of BRAF class II/III-mutant cell li… (full text at CIViC)

PMID 38588399 · Ryan et al., 2024 · Open in CIViC

In an in vitro study, a PC-9 cell line expressing BRAF G469A mutation demonstrated decreased sensitivity to erlotinib treatment compared to PC-9 cells expressing BRAF wild-type. Sensitivity was determ… (full text at CIViC)

PMID 22773810 · Ohashi et al., 2012 · Open in CIViC

PC9 cells harboring an in-frame deletion in exon 19 of the EGFR gene were cultured in the presence of increasing concentrations of osimertinib. Three clones resistant to osimertinib were isolated and … (full text at CIViC)

PMID 31502118 · La Monica et al., 2019 · Open in CIViC

Case report of a patient with NSCLC and BRAF G469R mutation who showed a dramatic response to sorafenib.

PMID 26237499 · Sereno et al., 2015 · Open in CIViC

Non-V600 BRAF mutations occur frequently in NSCLC. BRAF G469S increases kinase activity, as it can induce MEK/ERK activation to higher levels that wild-type BRAF when expressed in HEK293T cells. BEAS-… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

Non-V600 BRAF mutations occur frequently in NSCLC. BRAF G469V increases kinase activity, as it can induce MEK/ERK activation to higher levels that wild-type BRAF when expressed in HEK293T cells. BEAS-… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

Case report of a patient with HCC and NSCLC (only NSCLC harboring the BRAF G469V mutation). Sorafenib at standard dosage led to a partial response in the primary lesion of the lung, complete response … (full text at CIViC)

PMID 27388325 · Casadei Gardini et al., 2016 · Open in CIViC

Non-V600 BRAF mutations occur frequently in NSCLC. While BRAF G596C results in impaired kinase activity, it can induce MEK/ERK activation when expressed in HEK293T cells in the presence of RAF1 (CRAF)… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

Non-V600 BRAF mutations occur in about half of BRAF-mutated lung cancers, and their sensitivity to Dabrafenib and Trametinib is not well documented. In a cohort of 229 NSCLC patients that underwent mo… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

In a retrospective study of 35 lung adenocarcinoma patients (chemotherapy previously administered in 86% of patients), a patient harboring a BRAF G596V mutation was associated with partial response to… (full text at CIViC)

PMID 26200454 · Gautschi et al., 2015 · Open in CIViC

Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 20 patients with non-small-cell-lung cancer (17 with BRAF V600E, one with BRA… (full text at CIViC)

PMID 26287849 · Hyman et al., 2015 · Open in CIViC

Patients with BRAF V600E-mutant NSCLC (n=57) were enrolled into a phase 2, multicentre, non-randomised, open-label study, administering dabrafenib plus trametinib. The overall response rate was 36/57 … (full text at CIViC)

PMID 27283860 · Planchard et al., 2016 · Open in CIViC

In a genetic screen of 87 lung cancer cell lines, one MEK-dependent cell line HCC364 contained a BRAF-V600E mutation. In growth assays, the MEK inhibitor PD-0325901 reduced proliferation in growth ass… (full text at CIViC)

PMID 19010912 · Pratilas et al., 2008 · Open in CIViC

A 42 year old man with non-smoking history presented with EGFR L858R positive lung adenocarcinoma. He was given various treatments including erlotinib and gefitinib and progressed four years later. bi… (full text at CIViC)

PMID 29074209 · Bearz et al., 2017 · Open in CIViC

In a clinical study of 49 patients, 10 patients with Non-Small Cell Lung Cancer (NSCLC) and wild-type BRAF gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of… (full text at CIViC)

PMID 33090333 · Fisher et al., 2020 · Open in CIViC

Samples from 393 patients with NSCLC were evaluated for 3 SNPs in CBLB (rs1042852, rs2305035, and rs7649466). Genotypes rs7649466 and rs1042852 were not associated with a change in clinical outcome c… (full text at CIViC)

PMID 26732495 · Li et al., 2016 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

Case report of a 60-year old woman with lung adenocarcinoma. After negative testing for EGFR mutations and ALK translocations and failure of platinum-based chemotherapy she was enrolled on a nintedani… (full text at CIViC)

PMID 26787234 · Takeda et al., 2016 · Open in CIViC

Inceased copy number of CCND1 is associated with poorer overall survival.

PMID 17070615 · Gautschi et al., 2007 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

Three studies have found no significant survival impact for CCND1 in lung cancer.

PMID 17070615 · Gautschi et al., 2007 · Open in CIViC

Three studies have associated CCND1 expression with poorer survival.

PMID 17070615 · Gautschi et al., 2007 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

This meta-analysis did not find a significant connection between expression of PD-L1 and overall survival in patients with NSCLC.

PMID 26664143 · Zhong et al., 2015 · Open in CIViC

In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study).

PMID 26313362 · Schmidt et al., 2015 · Open in CIViC